PREVENT: Eculizumab May Lower Relapse Risk in NMOSD

This article was originally published here

Use of eculizumab resulted in significantly greater relapse reduction over placebo in patients with neuromyelitis optica spectrum disorder (NMSOD), new findings from the phase 3 PREVENT trial show.
Medscape Medical News